MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04253nam a22007097a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
160923s20152015 xxu||||| |||| 00|Ovid MEDLINE(R) |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1745-6215 |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
26590128 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
A randomized pilot study on the effect of niacin on pulmonary arterial pressure. |
| 251 ## - Source |
|---|
| Source |
Trials [Electronic Resource]. 16:530, 2015. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Trials. 16:530, 2015. |
| 253 ## - Journal Name |
|---|
| Journal name |
Trials |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2015 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2016 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2017-03-06 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online through MWHC library: 2006 - present |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
BACKGROUND: Niacin induces the release of vasodilating prostaglandins, for which receptors are present within the pulmonary arterial circulation. We hypothesized that immediate-release niacin would reduce right ventricular systolic pressure in patients with pulmonary hypertension in a randomized, double-blinded, single-dose provocation study. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: A single dose of immediate-release niacin (100 mg or 500 mg) had no significant effect on RVSP 1 hour post administration. A nonsignificant dose-dependent trend for a modest reduction in RVSP, most notable in the 500 mg group, was noted. (ISRCTN number 12353191, registered April 23, 2015). |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: We recruited inpatient subjects with a Doppler echocardiogram showing a peak tricuspid regurgitation (TR) jet velocity of 2.7 m/s or greater, and who were free of known pulmonary vascular disease. Subjects were randomized in a 1:2:2 ratio to receive a single dose of either placebo, niacin 100 mg or niacin 500 mg, respectively. TR jet velocities were measured immediately before, and 1 hour post dose, corresponding to peak niacin absorption and prostaglandin release. The primary endpoint was the change in mean TR jet velocity measured over ten successive cardiac cycles. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: The baseline mean estimated right ventricular systolic pressure (RVSP) for all 49 subjects (25 male) was 51.9+/-12.1 mm Hg. The primary endpoint of mean change in TR jet velocity was 0.016+/-0.065 m/s in the placebo group, compared to -0.017+/-0.065 m/s with niacin 100 mg, and -0.063+/-0.038 m/s with niacin 500 mg (P=0.63). The change in maximum estimated RVSP across the three drug groups was 0.2+/-1.6 mm Hg, -1.3+/-1.8 mm Hg and -2.2+/-1.2 mm Hg (P=0.62). In exploratory pairwise analysis in the high-dose niacin group (500 mg), the reduction in mean RVSP was from 50.9+/-9.4 mm Hg to 48.7+/-10.0 mm Hg (P=0.09). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Antihypertensive Agents/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Arterial Pressure/de [Drug Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Hypertension, Pulmonary/dt [Drug Therapy] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Niacin/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Pulmonary Artery/de [Drug Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
*Vasodilator Agents/tu [Therapeutic Use] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Aged, 80 and over |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Antihypertensive Agents/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
District of Columbia |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Double-Blind Method |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Echocardiography, Doppler |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Female |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Humans |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hypertension, Pulmonary/pp [Physiopathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Hypertension, Pulmonary/us [Ultrasonography] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Male |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Middle Aged |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Niacin/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pilot Projects |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pulmonary Artery/pp [Physiopathology] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Pulmonary Artery/us [Ultrasonography] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Time Factors |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Treatment Outcome |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Vasodilator Agents/ae [Adverse Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Ventricular Function, Right/de [Drug Effects] |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Ventricular Pressure/de [Drug Effects] |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Randomized Controlled Trial |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Research Support, Non-U.S. Gov't |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Dooley, Daniel J |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
McNamara, Martin J |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Sayanlar, Jason J |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Srichai, Monvadi B |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Taylor, Allen J |
| 790 ## - Authors |
|---|
| All authors |
Dooley DJ, McNamara MJ, Sayanlar JJ, Srichai MB, Taylor AJ |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="http://dx.doi.org/10.1186/s13063-015-1013-6">http://dx.doi.org/10.1186/s13063-015-1013-6</a> |
| Public note |
http://dx.doi.org/10.1186/s13063-015-1013-6 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
